Analysts Set Aratana Therapeutics Inc (PETX) Target Price at $8.50

Aratana Therapeutics Inc (NASDAQ:PETX) has been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.50.

A number of brokerages recently weighed in on PETX. Stifel Nicolaus restated a “hold” rating and set a $6.00 price objective on shares of Aratana Therapeutics in a research report on Monday, December 18th. CL King began coverage on Aratana Therapeutics in a research report on Wednesday, December 27th. They set a “neutral” rating on the stock. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Zacks Investment Research upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Finally, HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 19th.

How to Become a New Pot Stock Millionaire

Shares of PETX stock traded down $0.13 during mid-day trading on Wednesday, reaching $3.95. The company had a trading volume of 602,219 shares, compared to its average volume of 465,013. The company has a market cap of $187.09, a price-to-earnings ratio of -3.35 and a beta of 3.13. Aratana Therapeutics has a twelve month low of $3.67 and a twelve month high of $7.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.40 and a quick ratio of 2.02.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. The business had revenue of $10.46 million for the quarter, compared to analyst estimates of $5.72 million. Aratana Therapeutics had a negative return on equity of 45.15% and a negative net margin of 185.78%. sell-side analysts anticipate that Aratana Therapeutics will post -0.61 earnings per share for the current fiscal year.

In other Aratana Therapeutics news, CEO Peter Steven St sold 19,367 shares of the company’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total value of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Craig A. Tooman sold 30,000 shares of the company’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the completion of the sale, the insider now owns 75,024 shares in the company, valued at approximately $395,376.48. The disclosure for this sale can be found here. Insiders own 5.20% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PETX. Voya Investment Management LLC boosted its holdings in shares of Aratana Therapeutics by 22.7% in the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 3,610 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Aratana Therapeutics in the fourth quarter worth about $110,000. Parametric Portfolio Associates LLC grew its stake in shares of Aratana Therapeutics by 6.6% in the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 1,875 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Aratana Therapeutics by 25.3% in the second quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 6,898 shares during the last quarter. Finally, Ellington Management Group LLC bought a new stake in shares of Aratana Therapeutics in the fourth quarter worth about $304,000. Hedge funds and other institutional investors own 71.07% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3296644/analysts-set-aratana-therapeutics-inc-petx-target-price-at-8-50.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group
Show  Reaches Market Cap of $0.00
Show Reaches Market Cap of $0.00
PayCoin  Price Tops $0.0344 on Major Exchanges
PayCoin Price Tops $0.0344 on Major Exchanges
UGAIN Price Reaches $0.0031
UGAIN Price Reaches $0.0031
Reviewing Sally Beauty  and Kirkland’s Home
Reviewing Sally Beauty and Kirkland’s Home
Comparing CGG  and Paramount Resources
Comparing CGG and Paramount Resources


© 2006-2018 Ticker Report. Google+.